Although use of MGBG has fallen into disfavor because of its toxicity, there has been a resurgence of clinical interest in this drug as less-toxic dose schedules have been developed (9). MGBG also is being tested in combination with other anticancer agents (8) in attempts to enhance selectively its therapeutic efficacy. Of particular interest to us has been the potential use of MGBG in combination with a-difiuoromethylorrnthine, the irreversible inhibitor of ornithine decarboxylase (EC 4.1.1.17) (10), the enzyme that catalyzes the rate-limiting step in polyamine biosynthesis. Phase I trials of this combination (11,12), however, showed marked potentiation of MGBG toxicity, which emphasizes the importance of monitoring the concentration of MGBG during treatment.
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Methylglyoxal bis(guanylhydrazone) (MGBG; NSC-32946), also known as "methyl-GAG," is a potent antineoplastic agent (1-4) and a reversible inhibitor of S-adenosylmethionine decarboxylase (EC 4.1.1.50) (5) , an enzyme involved in synthesis of the polyamines spermidine and spermine from putrescine. MGBG also inhibits diamine oxidase EEC 1.4.3.6; amine oxidase (copper containing)] (6), the enzyme involved in the metabolism of putrescine. A detailed review of MGBG (7) , recently updated (8), includes some of the current considerations for the use of this agent.
Although use of MGBG has fallen into disfavor because of its toxicity, there has been a resurgence of clinical interest in this drug as less-toxic dose schedules have been developed (9) . MGBG also is being tested in combination with other anticancer agents (8) in attempts to enhance selectively its therapeutic efficacy. Of particular interest to us has been the potential use of MGBG in combination with a-difiuoromethylorrnthine, the irreversible inhibitor of ornithine decarboxylase (EC 4.1.1.17) (10), the enzyme that catalyzes the rate-limiting step in polyamine biosynthesis. Phase I trials of this combination (11,12), however, showed marked potentiation of MGBG toxicity, which emphasizes the importance of monitoring the concentration of MGBG during versed-phase (14) or reversed-phase ion-pair (15, 16) "highperformance" liquid chromatography (HPLC) for separation, with detection at 283 am. A gas-chromatographic-mass-spectroscopic assay for MGBG has also been reported (17) . Unlike the enzymic assays for MGBG, the chromatographic assays require neither specially purified enzymes nor the use of radioisotopes, and they should be less susceptible to nonspecific interference.
Although they are also potentially more sensitive than the enzymic assays, the sensitivity of two of the three HPLC methods is compromised by interfering peaks, which necessitates sample clean-up with ion-exchange resins (14,16) or organic solvent extraction (15); the gas-chromatographic-mass-spectroscopic assay (17) , in addition, requires sample derivatization before analysis. For high-volume applications of the assay, the enzymic assay is too cumbersome and the assay times of 10 to 20 mm per sample for the chromatographic systems are limiting.
Here we report the development of a sensitive, relatively rapid method of analysis for MGBG in biological samples by reversed-phase ion-pair HPLC. 
Materials and Methods

Apparatus
Chromatographic Conditions
Isocratic elution, done with the use of only one of the system's two HPLC pumps, was performed at room temperature and a flow rate of 3.0 mL/min, which produced a backpressure of 13 Before we ran samples, we equilibrated the column with the mobile phase for 5 mm, using a flow rate of 4 mL/min. At the end of each set of samples, we washed the column with water for 30 mm at 2 mLfmin, followed by a changeover gradient to 100% methanol during 20 miii. The methanol wash was then continued for an additional 20 miii.
Procedures
We obtained signed informed-consent forms and collected samplesof plasma,urine, and bone-marrow leukocytes from patientswho were being treated with MGBG, obtained from the National Cancer Institute, Bethesda,MD 20205.
Procedure for plasma.
In a 2-mL polypropylene microcentri#{241}tge tube, place 1.5 mL of plasma and 375 4, of an ice- as required, to adjust the pH of the supernate fluid to 6.5 to 7.8. Do not expose the samples to perchloric acid for longer than 60 mm beforeadding KOH, to prevent loss of MGBG.
Excess KOH must also be avoided for the same reason. After keeping the sample on crushed ice for 30 mm, centrifuge (5000 x g, 4#{176}C, 5 miii) to precipitate potassium perchlorate. Filter the supernate (GVWP; Millipore) and transfer it to a 1-mL glass autosampler vial. Inject 250 4, of the sample.
Procedure
for urine. Collect urine in plastic bottles containing 10 mL of toluene as a preservative and store at -20 #{176}C. Before applying the sample, activate the Sep-Pak5 C18 cartridge (Waters Associates, Milford, MA 01757) by passing 2.5 mL of methanol through it, followed by 10 mL of water. Do not allow air to enter the cartridge until after the sample has been applied. High concentrations of MGBG appear in urine after MGBG infusion, so dilute such samples 10-fold with water: Attach the barrel of a 3-mL polypropylene syringe to the top of the cartridge, to serve as a reservoir. Transfer 1.5 mL of sample into the Sep-Pakreservoir, using a pipette fitted with a polypropylene tip. Apply the sample onto the cartridge by inserting the plunger into the syringe. Wash the cartridge with 3 mL of water and express all liquid from the cartridge with 3 mL of air. Elute MGBG from the Sep Recovery of MGBG was determined by adding MGBG to pooled, untreated (i.e., drug-free) normal human plasma and urine and comparing the peak heights for the drug extracted from these sample matrices, after correction for dilution, with that of equivalent standards in the methanol/acetic acid mixture. MGBG was added at two concentrations, 0.4 and 2.0 mol/L. Samples were prepared as described above, except that urine samples were not diluted before application onto the Sep-Paks.
Analyses were performed in triplicate on each of four separate days. Within-day and between-day variations were determined by assaying a plasma and urine sample, containing a known concentration of MGBG, three times per day on each of four days.
Interference studies. Several drugs and some ultravioletabsorbing primary amines were tested for potential interference in the assay. These were either dissolved in the methanol/acetic acid mixture or extracted, with methanol, from pulverized tablets and diluted with four volumes of 0.15 mol/L acetic acid. The suspensions were filtered (GVWP; Milhipore) and diluted with the methanol/acetic acid mixture, as required, to give a concentration exceeding their therapeutic range by 10-fold. First, we injected a 250-4, aliquot of each of these solutions directly into the chromatograph.
Those agents that were both retained on the analytical column and absorbed at 283 mm were then mixed with various amounts of MGBG and re-injected to determine how well they were resolved from the MGBG peak (18). In addition, we obtained pretreatment samples from each patient about to undergo MGBG therapy, and screened these for potential interfering peaks. outside the linear range were diluted and re-extracted. The lower limit of detection for MGBG (peak height twice that of the baseline noise) was 20 nmol/L. We calibrated the assay daily for maximum precision. We evaluated the precision of the assay (Table 1) at two concentrations of MGBG. We divided both a drug-free pool of human plasma and a drug-free human urine into two aliquots and added MGBG to a final concentration of either 400 or 2000 nmol/L. For triplicate analysis of these samples on each of four days, the within-day CVs ranged from 0.9% to 2.9% and the between-day CVs ranged from 4.2% to 6.2%. Using the same samples, we determined the analytical recovery of MGBG to be quantitative (101.0 ± 1.7%, mean ± SEM, n = 24) for both plasma and urine at both MGBG concentrations.
Results
We tested 12 compounds for potential analytical interference (Table 2) . We chose these compounds because they were either commonly used drugs, agents administered to the patients during the clinical studies-i.e., acetaminophen, hydromorphone (Dilaudid), and lorazepam-or compounds that absorbed at 283 nm and were expected to be retained on the column similarly to MGBG-i.e., dopamine, tyramine, and tryptamine.
All of these substances eluted before MGBG, and none interfered with the quantification of MGBG. Tryptamine was the only substance to elute near MGBG, with a retention time of 1.02 mm, but the two peaks were more than 98% resolved. Additionally, we observed no interfering peaks in specimens either from cancer patients before MGBG treatment or from otherwise normal individuals who had taken one or more of the commonly used drugs.
The application of this method to clinical samples is illustrated in Figures 3 and 4 . Figure 3 shows chromatograms of urine specimens obtained from a cancer patient (A) before treatment with MGBG and (B) after an MGBG infusion of 500 mg/rn2 (body surface area) over a 1-h period. Before treatment, no peak corresponding to MGBG was detected in the urine. Six days after the MGBG infusion (day 7), the concentration of MGBG in the 24-h urine was 47.6 pznol/L, or a total output of 15.3 mg of MGBG on that and a high flow rate (3 to 4 mL/min). Our system fits this description except that we used a 5-pm particle column because the high efficiency of a 3-pm < particle column was not required. Using 1-octanesulfonate as the counter-ion provided sufficient column capacity for resolving MGBG from unretained sample components. Because MGBG has two aininoguanidine groups available for ion-pairing, we could selectively retain MGBG on the col- From this relationship we estimated the MGBG excreted on days 4,5, and 6-for which specimens were not collected-to be 2.8, 2.5, and 2.1% of the infusion dose, respectively, and the cumulative amount of MGBG excreted by day 7 to be only 32.3% of the infusion dose. Both the biphasic pattern of umn by increasing the concentration of the 1-octanesulfonate. This effect of ion-pair concentration on column selectivity has not been generally recognized (18).
Our method offers several advantages over the other
HPLC methods (14-16) and the gas-chromatographic-mass-.
., spectroscopic rnetnuu (17) ior IVP.XDtT. rirst, Wi eluting m 1.67 nun, this method is three-to 10-fold faster than previous methods. Moreover, this method is five-to 50-fold more sensitive than the other three liquid chromatographic methods for plasma and tissue samples and 10-to 2000-fold more sensitive for urine samples. With this increased sensitivity we could measure cellular MGBG content in 1 X i0 to 106 leukocytes from bone-marrow aspirates. Two of the previously reported HPLC methods (14,15) encountered interfering peaks, especially in urine, that reduced the sensitivity of the assay; no interfering peaks were encountered in our assay. We were also able to increase sensitivity over the assay of Marsh et al. (16) by using a 250-p.L sample loop. The use of so large a sample loop on such a small column may not be generally acceptable, but the high resolution of our system permitted its use.
The lack of interference in our assay enabled us to use a simplified sample-preparation procedure. For the two moresensitive previously reported HPLC methods, both plasma
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and urine samples had to be deproteinized, either with perchloric acid plus extraction on a cation-exchange resin (16) or with methanol plus organic extraction (15) . For the gas-chromatographic-mass-spectroscopic assay, urea denaturation of samples was followed by extraction on a cationexchange column and derivatization before chromatography (17) . We found that deproteinization with perchloric acid produced clear extracts but resulted in a time-dependent, irreversible loss of MGBG, which could be prevented only if the extract were neutralized with KOH within 1 h after addition of the acid. After neutralization, the MGBG was stable for at least 24 h when stored at 4#{176}C. The instability of MGBG in perchloric acid without neutralization could explain the lower, variable recoveries previously reported (14).
As others have noted (14), we also found that addition of excess KOH resulted in loss of MGBG. These losses of MGBG were accompanied by the appearance of a tailing shoulder, which eventually formed multiple peaks in the elution proffle. Presumably, these changes could be monitored to detect potential extraction artifacts.
We were unable to find a suitable alternative deproteirnzationagent in which MGBG would be more stable. however, we also extracted MGBG from undiluted urine to test the effect of sample volume on the cartridge capacity. Recovery of 32 nmol of MGBG in 8 mL of undiluted urine, extracted by a single Sep-Pak, was complete(results not shown). By comparison, in the 10-folddiluted urine sample from day 1 (Table 3) , 30 nmol ofMGBG was applied onto the Sep-Pak. We empirically determined the minimal amount of methanol in the desorbingeluent that would provide complete recovery of MGBG from the cartridge, without being so strong as to alter the elution proffle of MGBG from the analytical system.
We quantified results by using external standards.
The theoretical considerations and limitations on the use of an internal standard and its effect on assay precisienhave been previously addressed (18,21) . Based on these considerations and the unavailability of a suitable potential internal standard, e.g., the MGBG homolog ethylglyoxal bis(guanylhydrazone), we designed this method to obviate the need for an internal standard.
For this assay, an internal standard would not improve precision because sample injection, which otherwise is the principal source of error for the external standard calibration procedure, includedthe entire contents of a ifiled sample-injectionloop.In addition, use of an internal standard would not correctfor potential errors in sample preparation. We alsoexpect that the ethyl homelog of MGBG would similarly be adversely affected by prolonged exposure to perchioric acid or excess KOH and could not correct for their effects on MGBG. For the urine extraction procedure, including an internal standard would reduce assay precision, given the additive error of measuring the heights of two peaks for quantification, and would not correct for any potential overload of the Sep-Pak cartridge. As stated previously, analytical recovery of MGBG was quantitative, and the within-day CV, for both sample preparation procedures, was 0.9% to 2.9%. This method offers several advantages to the clinical laboratory. Because of its speed and short set-up and equilibration times, less than 1 h, a dedicated system is not required.
Development of the separation conditions is also rapid, requiring only one day. In addition, we use a guard column, which is less costly than a 15-or 25-cm analytical column. By adding an integrator and a more-sophisticated autosampler, this method can be completely automated. This approach of "high-speed" reversed-phase ion-pair HPLC has recently been applied to the analysis of catecholamines (22) and can potentially be applied to the assay of other polar compounds. 
